Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects

Phase 4

Completed

• Conditions: Healthy

• Registration Number: NCT00345202
• Lead Sponsor: Regional Hospital Holstebro

Brief Summary

We wanted to test the shortterm effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, renal tubular function and vasoactive hormones on healthy subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Primary Completion: 2005-02
• Study Completion: 2005-02
• Study First Submitted: 2006-06-24
• Study First Submitted QC: 2006-06-26
• Study First Posted: 2006-06-27
• Status Verified: 2008-05
• Last Update Submitted: 2008-05-14
• Last Update Posted: 2008-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Both men and women
• Age: Between 20-50
• BMI<30

Exclusion Criteria

• Cl. signs or history of disease of heart, lungs, kidneys or endocrine organs.
• Abnormal lab. tests( haemoglobin, pl. sodium, pl. potassium, pl.creatinine, pl.bilirubin, pl.ALAT, pl. cholesterol, blood glucose)
• Albuminuria or glucosuria
• Cancer
• Art. hypertension
• Alcohol abuse
• Med. treatment, except oral contraceptives
• Pregnancy or breast feeding
• Blood donation less than 1 month before study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
GFR
RPF
FEna
FELi
CLna
CLli

Trial Locations

Locations (1)

Medical research unit, Department of medicin, Holstebro Sygehus; 🇩🇰 Holstebro, Ringkøbing countie, Denmark